Optimal TKI use for oncogene-addicted non-small cell lung cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses optimizing the use of tyrosine kinase inhibitors (TKIs) and movement towards personalized approaches for the treatment of patients with “oncogene-addicted” non-small cell lung cancer, including epidermal growth factor receptor (EGFR)-mutant and anaplastic lymphoma kinase (ALK)-mutant patients.

Share this video